Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019 12 10; 3(23):4136-4146.